Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized Phase II Clinical Trial on Intratumoral AS01B/Ipilimumab Plus Intravenous Nivolumab With or Without Autologous CD1c(BDCA-1)+ / CD141(BDCA-3)+ Myeloid Dendritic Cells.

NCT03707808 is registered in ClinicalTrials.gov with Universitair Ziekenhuis Brussel as lead sponsor.

NCT NCT03707808
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03707808 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized Phase II Clinical Trial on Intratumoral AS01B/Ipilimumab Plus Intravenous Nivolumab With or Without Autologous CD1c(BDCA-1)+ / CD141(BDCA-3)+ Myeloid Dendritic Cells.
Lead sponsor
Universitair Ziekenhuis Brussel
Phase
Phase 1/2
Overall status
Active, not recruiting
Start date
January 29, 2018
Completion date
December 23, 2027
Enrollment
18 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

metastases to soft tissue, solid tumor